InventisBio Co., Limited (SHA:688382)

China · Delayed Price · Currency is CNY

22.41

+0.87 (4.04%)

At close: Jul 10, 2026

-29.42% (1Y)

Market Cap	12.96B -35.6%
Revenue (ttm)	71.64M -57.5%
Net Income	-303.73M
EPS	-0.53
Shares Out	578.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,073,231
Open	21.43
Previous Close	21.54
Day's Range	21.06 - 23.58
52-Week Range	15.58 - 49.68
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About InventisBio

InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China. Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer; Taragarestrant (D-0502), which is in phase III and II to treat estrogen receptor positiv... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Employees 182

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688382

Full Company Profile

Financial Performance

In 2025, InventisBio's revenue was 37.29 million, a decrease of -77.91% compared to the previous year's 168.79 million. Losses were -316.87 million, 31.9% more than in 2024.

Financial Statements